NDAORALSUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VARIBAR HONEY (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARIBAR HONEY is an oral barium sulfate suspension used as a radiographic contrast agent for X-ray imaging procedures. It enables visualization of the gastrointestinal tract during diagnostic imaging studies. The product works by opacifying the GI tract to enhance radiographic contrast and image clarity.
Peak
Peak lifecycle stage indicates stable market position with established commercial infrastructure, though limited growth opportunities suggest moderate team size and focus on market defense.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
Working on VARIBAR HONEY offers exposure to the diagnostic imaging market and experience managing a stable, peak-stage product within Bracco's diversified portfolio. Career progression emphasizes commercial excellence, account management, and defending market share against internal Bracco competitors rather than pursuing innovation-driven growth.
Worked on VARIBAR HONEY at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.